Brian Taylor Slingsby - Feb 13, 2025 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Director, 10%+ Owner
Signature
Brian Taylor Slingsby by: /s/ Adam Levy, Attorney-in-fact
Stock symbol
MLYS
Transactions as of
Feb 13, 2025
Transactions value $
$0
Form type
4
Date filed
2/24/2025, 06:59 PM
Previous filing
Jul 26, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Award $0 +32.9K $0.00 32.9K Feb 13, 2025 Common Stock 32.9K $10.20 Direct F1
transaction MLYS Stock Option Other $0 -32.9K -100% $0.00 0 Feb 13, 2025 Common Stock 32.9K $10.20 Direct F1, F2
transaction MLYS Stock Option Other $0 +32.9K $0.00 32.9K Feb 13, 2025 Common Stock 32.9K $10.20 See footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests in 12 substantially equal monthly installments following the date of grant.
F2 Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP.
F3 Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, which is the general partner of Catalys Pacific Fund GP, LP. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.